JPRN-UMIN000044389招募中未知
Examination of reduction of hepatic fat mass and hepatic fibrosis inhibitory effect of pemafibrate in type 2 diabetic patients with hyperlipidemia and non-alcoholic fatty liver - Expectation Trial
Department of Endocrinology and Metabolism, Dokkyo Medical University0 个研究点目标入组 60 人开始时间: 2021年6月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Type 1 diabetes 2)Liver dysfunction (hepatic enzymes more than three times the upper limit of normal ranges) 3)A pregnant woman and/or a woman under breast-feeding 4)Impaired kidney function (serum creatinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women) 5)Diabetic proliferative retinopathy 6)The patients who has an anamnesis of hypersensitivity to the ingredient of a trial drug 7)No treatment with other fibrate 8)Patient with intolerance of medical reasons by doctor.
研究者
相似试验
招募中
不适用
Mechanisms of hepatic fat reduction through nutritional strategies in patients with indication for bariatric surgeryE66.82DRKS00009509Deutsches Institut für Ernährungsforschung Potsdam- Rehbrücke, Abteilung Klinische Ernährung60
进行中（未招募）
不适用
To evaluate detoxification and body fat mass decrease effect and safety of Wellnessup® diet: 4-weeks, Clinical trialKCT0003002Chonbuk National University Hospital45
已完成
不适用
Examination study on abdominal visceral fat reducing action by functional food intake -Randomized placebo-controlled double-blind parallel group comparison studyot applicableJPRN-UMIN000026291Maruzen Pharmaceuticals Co., Ltd.70
已完成
不适用
Effects of Weight Loss on Hepatic and Muscle Lipid Content and on Insulin Sensitivity on Obese Adolescents With NAFLDFatty LiverInsulin ResistanceNCT00585299Yale University4
已完成
4 期
Study for the effect of visceral fat reduction by SGLT2 inhibitor Ipragliglozinin patients with type 2 diabetestype 2 diabetes mellitusJPRN-UMIN000014058Hokkaido University Hospital26